| Display title | Chemistry:Tazemetostat |
| Default sort key | Tazemetostat |
| Page length (in bytes) | 9,980 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 339303 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Wikisleeper |
| Date of page creation | 00:16, 27 June 2023 |
| Latest editor | imported>Wikisleeper |
| Date of latest edit | 00:16, 27 June 2023 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Tazemetostat, sold under the brand name Tazverik, is a medication used for the treatment of adults and adolescents aged 16 years and older with metastatic (when cancer cells spread to other parts of the body) or locally advanced (when cancer has grown outside the organ it started in, but has not yet... |
